News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,636 Results
Type
Article (13841)
Company Profile (109)
Press Release (251686)
Section
Business (88640)
Career Advice (475)
Deals (15437)
Drug Delivery (64)
Drug Development (36947)
Employer Resources (49)
FDA (6333)
Job Trends (6251)
News (151317)
Policy (14120)
Tag
Academia (471)
Alliances (23343)
Alzheimer's disease (379)
Approvals (6346)
Artificial intelligence (74)
Bankruptcy (145)
Best Places to Work (4416)
Breast cancer (65)
Cancer (453)
Cardiovascular disease (47)
Career advice (416)
Cell therapy (64)
Clinical research (30931)
Collaboration (234)
Compensation (97)
COVID-19 (764)
C-suite (74)
Data (463)
Diabetes (64)
Diagnostics (1261)
Drug discovery (45)
Drug pricing (59)
Earnings (31830)
Events (37493)
Executive appointments (256)
FDA (6606)
Funding (153)
Gene therapy (77)
GLP-1 (321)
Government (1289)
Healthcare (3667)
Infectious disease (787)
Inflammatory bowel disease (50)
Interviews (61)
IPO (5900)
Job creations (2056)
Job search strategy (379)
Layoffs (173)
Legal (3430)
Lung cancer (64)
Manufacturing (112)
Medical device (1385)
Medtech (1388)
Mergers & acquisitions (9634)
Metabolic disorders (198)
Neuroscience (506)
NextGen: Class of 2025 (1608)
Non-profit (635)
Northern California (560)
Obesity (118)
Opinion (116)
Patents (71)
People (28874)
Pharmaceutical (67)
Phase I (8082)
Phase II (13070)
Phase III (11741)
Pipeline (239)
Policy (47)
Postmarket research (1406)
Preclinical (3233)
Radiopharmaceuticals (122)
Rare diseases (117)
Real estate (2644)
Regulatory (10012)
Research institute (580)
Resumes & cover letters (56)
Southern California (533)
Startups (1638)
United States (5376)
Vaccines (124)
Weight loss (86)
Date
Today (17)
Last 7 days (246)
Last 30 days (764)
Last 365 days (12580)
2025 (579)
2024 (12709)
2023 (14515)
2022 (19768)
2021 (20378)
2020 (19311)
2019 (15128)
2018 (11897)
2017 (14059)
2016 (13298)
2015 (15645)
2014 (12514)
2013 (10648)
2012 (11494)
2011 (12046)
2010 (10968)
Location
Africa (314)
Arizona (47)
Asia (20103)
Australia (2582)
California (1295)
Canada (714)
China (168)
Colorado (51)
Connecticut (54)
Europe (39658)
Florida (210)
Illinois (147)
Indiana (103)
Japan (59)
Kansas (53)
Maryland (186)
Massachusetts (1113)
Minnesota (70)
New Jersey (529)
New York (373)
North Carolina (316)
Northern California (560)
Pennsylvania (338)
South America (509)
Southern California (533)
Texas (171)
Virginia (49)
Washington State (86)
265,636 Results for "isa pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new subgroup analyses from Ionis and AstraZeneca’s Phase 3 NEURO-TTRansform study of WAINUA™ (eplontersen) at the 2024 International Symposium on Amyloidosis (ISA) in Rochester, Minnesota, May 26-30.
May 23, 2024
·
6 min read
Business
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024.
May 23, 2024
·
13 min read
Drug Development
ISA Pharmaceuticals reports highlights of randomized Phase 2 cancer vaccine trial in head & neck cancer
ISA Pharmaceuticals B.V. announced positive anti-tumor response data with ISA101b, an HPV16 directed therapeutic cancer vaccine given in combination with Libtayo®, an anti-PD1 checkpoint inhibitor.
December 12, 2023
·
4 min read
Drug Development
ISA Pharmaceuticals to Present First Clinical Trial Data from the Phase II Study of ISA101b and Libtayo® (cemiplimab) Combination in Head and Neck Cancer at the ASCO Annual Meeting 2023
ISA Pharmaceuticals B.V. announces that it will present the first clinical data of the combination of ISA101b and Regeneron’s PD-1 inhibitor Libtayo® in patients with recurrent metastatic Human Papilloma Virus type 16 induced head and neck cancers who progressed on pembrolizumab or nivolumab.
May 25, 2023
·
2 min read
Drug Development
First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study
ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat cancers and serious infectious diseases, is pleased to announce that the first patient has been dosed in the HEB-PEP study.
August 31, 2023
·
4 min read
The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy
ISA Pharmaceuticals B.V. presented the first clinical data of the combination of ISA101b and Regeneron’s anti-PD-1 Libtayo® at the ASCO annual meeting in Chicago.
June 6, 2023
·
2 min read
Biotech Bay
Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)
Attralus, Inc. announced 11 data presentations, including two oral presentations related to the use of 124I-evuzamitide, the company’s pan-amyloid binding imaging agent in development for the diagnosis of cardiac amyloidosis.
May 30, 2024
·
12 min read
Drug Development
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
BridgeBio Pharma, Inc. announced that 12 oral and moderated poster presentations will be shared at the 2024 International Symposium on Amyloidosis, taking place in Rochester, Minnesota on May 26 - 30, 2024.
May 24, 2024
·
5 min read
Drug Development
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced positive results of five new analyses of clinical endpoint events from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM.
May 29, 2024
·
10 min read
Press Releases
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
December 16, 2024
·
7 min read
1 of 26,564
Next
